z-logo
Premium
Efficacy and safety of lobeglitazone versus sitagliptin as an add‐on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks
Author(s) -
Kim Sin Gon,
Kim Kyoung Jin,
Yoon Kun Ho,
Chun Sung Wan,
Park Kyong Soo,
Choi Kyung Mook,
Lim Soo,
Mok JiOh,
Lee Hyoung Woo,
Seo Ji A.,
Cha BongSoo,
Kim Mi Kyung,
Shon Ho Sang,
Choi Dong Seop,
Kim Doo Man
Publication year - 2020
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14085
Subject(s) - sitagliptin , metformin , medicine , type 2 diabetes , metabolic syndrome , sitagliptin phosphate , confidence interval , diabetes mellitus , endocrinology , pharmacology , gastroenterology
Abstract We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add‐on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between‐group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non‐inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P  < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add‐on to metformin in terms of efficacy and safety.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here